Displaying 1 - 19 of 19
| Active Ingredient | CELECOXIB |
| Therapeutic Class | CYCLOOXYGENASE-2 (COX2) INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ETORICOXIB |
| Therapeutic Class | CYCLOOXYGENASE-2 (COX2) INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MELOXICAM |
| Therapeutic Class | CYCLOOXYGENASE-2 (COX2) INHIBITORS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | ASPIRIN |
| Therapeutic Class | SALICYLATES |
| Indications | Mild to moderate pain and fever, myocardial and stroke. |
| Caution | May cause G.I. bleeding, irritation, rashes, bronchospasm, nasal polyps. Contraindicated with G.I. ulceration, anticoagulants, bleeding disorders, gout and in children and adolescents with viral ill More ... |
| Dose Range | 300-900mg every 4-6 hours as necessary. Usual maximum 4g daily. Soluble or E.C. may be best for chronic use. See BDS supply protocols pg. 4 for maximum reimbursable quantities. |
| Drug Interactions | |
| Pregnancy | Use antiplatelet doses with caution during third trimester; impaired platelet fu More ... |
| Breast Feeding | Aspirin is distributed in breastmilk. Use with caution in lactating women. |
| Active Ingredient | DICLOFENAC POTASSIUM |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications | Short term treatment of mild to moderate pain where rapid onset of action is desired. Not supplied for chronic anti-inflammatory conditions. |
| Caution | Under Diclofenac Sodium. |
| Dose Range |
Adult: 25-50mg three times daily. Usually no more than a 5 day supply is needed. Primary dysmenorrhoea: 100mg initially, then 50mg 3 times daily to a maximum of 150mg daily. Children 1 year and over: 0.25-1ml/kg body weight daily depending on the sever |
| Drug Interactions | |
| Pregnancy | Avoid unless the potential benefit outweighs the risk. |
| Breast Feeding | Diclofenac is distributed in breastmilk and is not recommended in lactating wome More ... |
| Active Ingredient | DICLOFENAC SODIUM |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications | Pain and inflammation in rheumatic disorders in patients intolerant or resistant to aspirin and indomethacin. |
| Caution | G.I. irritation; allergic disorders (as for asp irin) but less frequent. c.f. prescribing in liver and renal disease p. 13; 28. |
| Dose Range |
Adult: 25-50mg every 6-8 hours or 75-150 mg in divided doses, or 100mg daily as a single dose using the Retard preparation. Take with food.Inj.: I.M. 25-50mg every 6-8 hours. Supp: 50mg at night or every 6-8 hours if tablets are not tolerated. See BDS sup |
| Drug Interactions | |
| Pregnancy | Avoid unless the potential benefit outweighs the risk. |
| Breast Feeding | Diclofenac is distributed in breastmilk and is not recommended in lactating wome More ... |
| Active Ingredient | IBUPROFEN |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications |
Mild to moderate pain. Alternative to aspirin or indomethacin, with less side effects. |
| Caution | G.I. irritation; allergic disorders (as for aspirin) but less frequent. May administer with meals or milk if G.I. upset occurs. C.f. prescribing in liver and renal disease p. 14; 31. |
| Dose Range | Adult: 400mg 3-4 times daily. Do not exceed 2400mg total daily dose. Pediatric: 4-10mg/kg every 6-8 hours to a maximum of 40mg/kg/day. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | Avoid unless the potential benefit outweighs the risk. |
| Breast Feeding | Ibuprofen is distributed in breastmilk. Use with caution in lactating women. |
| Active Ingredient | INDOMETHACIN |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications |
Pain and inflammation in rheumatic/musculo-skeletal disorders e.g. gout. To promote closure of patent ductus arteriosus in premature infants. |
| Caution | G.I. upset, frontal headaches, dizziness, abdominal pain, constipation, diarrhea. Contraindicated in peptic ulcers, salicylate hypersensitivity. C.f. prescribing in liver and renal disease p. 14; 33. |
| Dose Range |
100mg once a day, up to a maximum of 200mg in divided doses. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | Avoid unless the potential benefit outweighs the risk. |
| Breast Feeding | Indomethacin is distributed in breastmilk. Use with caution in lactating. |
| Active Ingredient | KETOPROFEN |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MEFENAMIC ACID |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | NAPROXEN |
| Therapeutic Class | OTHER NONSTEROIDAL ANTI-INFLAMMATORY AGENTS |
| Indications | Mild to moderate pain and inflammation in rheumatic and musculo- skeletal disorders. |
| Caution | May cause gastro-intestinal irritation. c.f. prescribing in liver and renal disease p.15;33. |
| Dose Range |
250mg-1g as a single or in divided doses. Take with food. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | Avoid unless potential benefit outweighs the risk. |
| Breast Feeding | Naproxen is distributed in breastmilk. Use is not recommended in pregnant women. |
| Active Ingredient | CODEINE PHOSPHATE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Mild to moderate pain in patients intolerant of aspirin. |
| Caution | Syncope, nausea, constipation, sedation, dependence. May cause drowsiness. Warn patients re driving: Avoid alcohol and other depressants. Avoid in children under 1 year old. |
| Dose Range | Adult: 30 60mg every 4 6 hours. Maximum 240mg daily. Reduce dose by 75% in moderate and 50% in severe renal failure. Take with food or milk. Paediatric under 12 years: 0.5-1mg/kgevery 4-6 hours. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | FENTANYL CITRATE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications |
Adjunct to general anaesthetics, anaesthetic for induction and maintenance. |
| Caution | Respiratory depression and apnea. Transient hypotension may follow intravenous dosage. An opiate antagonist and facilities for administration of oxygen and controlled respiration should be available More ... |
| Dose Range |
As an adjunct to general anesthesia, fentany l may be given in low-dose, moderate-dose, or high-dose regimens. Low dose: 2mcg/kg; moderate dose: initial IV dose of 2-20 mcg/kg is administered; additional doses of 25-100 mcg may be given IV or IM as nece |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MORPHINE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Severe visceral pain, post operative pain, terminal malignancies or bone pain, my ocardial infarction. |
| Caution | Drowsiness,nausea, vomiting, constipation,depression of respiration and cough. Urinary retention, tolerance and dependence. Advisable to use concurrent antiemetics and prophylaxis of constipation. |
| Dose Range |
Immediate release: 5-20mg every 4 hours. Loading dose may be required. Modified release given as once or twice daily dosing. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MORPHINE SULPHATE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Severe visceral pain, post operative pain, terminal malignancies or bone pain, my ocardial infarction. |
| Caution | Drowsiness,nausea, vomiting, constipation,depression of respiration and cough. Urinary retention, tolerance and dependence. Advisable to use concurrent antiemetics and prophylaxis of constipation. |
| Dose Range |
Immediate release: 5-20mg every 4 hours. Loading dose may be required. Modified release given as once or twice daily dosing. See BDS supply protocols pg. 5. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | MORPHINE SULPHATE SR |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | PETHIDINE |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Obstetric analgesia. |
| Caution | See morphine (but less constipating). |
| Dose Range | 50 to 100 mg may be given by intramuscular or subcutaneous injection as soon as contractions occur at regular intervals. This dose may be repeated after 1 to 3 hours if necessary up to a maximum of 400 mg in 24 hours. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SUFENTANYL |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Analgesic adjunct in anaesthesia and as a primary anaesthetic in procedures requiring assisted ventilation. Obstetric analgesia. |
| Caution | As for fentany l. |
| Dose Range |
Adjunct: Total IV dose should not exceed 1mcg/kg/hoir for procedures lasting up to 8 hours.Primary anaesthesia: 8-30mcg/kg with 100% oxygen.Obstetric analgesia: 10-15mck with 10ml bupivacaine 0.125% (or its equivalent), repeated twice at not less than 1 |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | TRAMADOL |
| Therapeutic Class | OPIATE AGONISTS |
| Indications | Moderate to severe pain. |
| Caution | Drowsiness, dizziness, headache, fatigue, restlessness, nausea, vomiting, constipation, dry mouth, diaphoresis. |
| Dose Range |
Adult and children 12 years and over: 50-100 mg every 4-6 hours or modified-release preparation once or twice daily, to a max.of 400mg daily. Reduce dose in patients with renal or hepatic dysfunction. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |